Thank you for participating in the 4 hour post-transfusion Initial Data Collection Form: US Expanded Access Program for Convalescent Plasma for the Treatment of Patients with COVID-19.

NOTE: Mayo Clinic will serve as the IRB of record. You are required by Federal Regulation to report Serious Adverse Events (SAEs), which are found in this Initial Data Collection Form (4-hour post-transfusion/unable to transfuse).

The Initial Data Collection (4-hour) Form should be completed for each enrolled patient, regardless of circumstances. For example, the form should be filled out even if plasma was never ordered or plasma was ordered but not transfused.

Please fill in the form with as much detail as possible.

Please use the unique patient code assigned at the time of enrollment to complete the form.

The purpose of the study is to provide access to investigational convalescent plasma for patients in acute care facilities infected with SARS-CoV-2 who have severe or life-threatening COVID-19, or who are judged by a healthcare provider to be at high risk of progression to severe or life-threatening disease.

Information, protocol, consent forms and site registration, enrollment and followup forms are available at

If you have any questions or difficulties please email, which will be monitored from 7am-7pm CST.

Note: Submission of this form on iOS devices using Safari may cause duplicate submissions. If possible, please submit from another browser such as Google Chrome, Internet Explorer, or Mozilla Firefox. Thank you.

Loading... Loading...
You have selected an option that triggers this survey to end right now. To save your responses and end the survey, click the button below to do so. If you have selected the wrong option by accident and do not wish to leave the survey, you may click the other button below to continue, which will also remove the value of the option you just selected to allow you to enter it again and continue the survey.
The response has now been removed for the last question for which you selected a value. You may now enter a new response for that question and continue the survey.